Moore David Scott purchased $250K of CRVS
Moore David Scott purchased 21,700 shares of Corvus Pharmaceuticals, Inc. (CRVS) at $11.53 ($0.25M total) on 2026-06-11.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market purchase size, price, and post-transaction holdings; it may slightly influence sentiment but does not change fundamentals in the text.
Market read
Traders may treat the buy as a small sentiment input, but there is no accompanying catalyst (earnings, trial data, guidance, or regulatory action) in the article.
What to watch
The filing notes no pre-arranged 10b5-1 plan, but the article provides no context on motivation, prior holdings, or whether other insiders are buying/selling.
Background
The article is an SEC Form 4 insider transaction disclosure for Corvus Pharmaceuticals, Inc.
Ticker impact
Corvus Pharmaceuticals director Moore David Scott filed an open-market purchase of 21,700 shares at $11.5316 on 2026-06-11.
Likely limited near-term impact; any effect would be sentiment-driven and small.
Form 4 insider buys can be informative, but this filing provides no new operational, clinical, or financial developments—only transaction details and no 10b5-1 plan.
Market effects
Minimal; single-company insider transaction without sector-wide regulatory/clinical updates.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine liquidity/portfolio rebalancing and may not reflect near-term business improvement.
Key entities
- issuerCorvus Pharmaceuticals, Inc.
Subject of the SEC Form 4 insider transaction disclosure (CRVS).
- insiderMoore David Scott
Director who reported an open-market purchase of 21,700 shares.